PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jobesJournal of Obesity
 
J Obes. 2017; 2017: 5272984.
Published online 2017 March 6. doi:  10.1155/2017/5272984
PMCID: PMC5358440

Association between Sleep Habits and Metabolically Healthy Obesity in Adults: A Cross-Sectional Study

Abstract

Higher body mass index (BMI) increases the risk of cardiometabolic diseases, but nearly a third of the people living with obesity (BMI: ≥30 kg/m2) are metabolically healthy (MHO). Extreme sleep durations and poor sleep quality are associated with higher bodyweight and cardiometabolic dysfunction, but the full extent to which sleep habits may help differentiate those with MHO versus metabolically abnormal obesity (MAO) is not yet known. Data from the U.S. National Health and Nutritional Examination Survey 2005–08 was used (BMI: ≥30 kg/m2; ≥20 y; N = 1,777). The absence of metabolic syndrome was used to define MHO. Those with MHO tended to be younger, female, Non-Hispanic Black, never smokers, more physically active, and with less physician diagnosed sleep disorders than MAO. Neither sleep duration nor overall sleep quality was related to MHO in crude or multivariable adjusted analyses; however, reporting “almost always” to having trouble falling asleep (OR (95% CI): 0.40 (0.20–0.78)), waking up during the night (0.38 (0.17–0.85)), feeling unrested during the day (0.35 (0.18–0.70)), and feeling overly sleepy during the day (0.35 (0.17–0.75)) was related to lower odds of MHO. Selected sleep quality factors, but not sleep quantity or overall sleep quality, are associated with the MHO phenotype.

1. Introduction

Despite the well-known complications of excess body fat [1, 2] emerging research suggests that up to 30% of people living with obesity (body mass index of ≥30 kg/m2) are metabolically healthy (MHO) [3]. MHO individuals may also be insulin-sensitive [4] and have a similar mortality risk as metabolically healthy normal bodyweight individuals [5, 6]. However, the existence of the MHO phenotype as a distinct entity, particularly over time, remains controversial [7]. Indeed, a recent meta-analysis suggests that, with longer follow-up, MHO individuals are at a 24% greater risk of cardiovascular events and all-cause mortality compared to the metabolically healthy normal-weight people whereas metabolically unhealthy individuals are at similarly elevated morbidity and mortality risks regardless of their body weight class [8]. Therefore, identifying factors that help maintain the metabolic health of individuals living with higher bodyweight may help reduce their morbidity and mortality risks.

Unique determinants that differentiate MHO and metabolically abnormal obesity (MAO) are largely unknown. However, lifestyle factors such as physical activity, weight history [911], dietary habits [3, 12, 13], and systematic inflammation and location of fats storage [14] have been found to differ between MHO and MAO. Sleep is another potential behavior that can vary between MHO and MAO phenotypes; however, in the only two studies conducted thus far, one found no difference in self-reported sleep duration between MHO and MAO [15], and the other found higher sleep duration in MHO women (MHO: 7.6 h versus MAO: 7.0 h), but not men [3]. Neither study [3, 15] evaluated the relationship between sleep quality alongside sleep duration and MHO. They either focused on middle-aged adults [3] or were limited by the application of ethnic-specific waist circumference cut-offs to a Korean sample [15]. To date, the relationship between sleep habits and the MHO phenotype amongst the U.S. adult population has yet to be studied. The primary purpose of this study was to, therefore, estimate the relationship between sleep duration and quality factors of MHO versus MAO in free-living U.S. adults.

2. Subjects and Methods

2.1. Sample

Data for this analysis was derived from the U.S. National Health and Nutrition Examination Survey (NHANES). Briefly, NHANES is a series of cross-sectional studies designed to assess the health and nutritional status of the U.S. population and includes demographic, socioeconomic, dietary, and health-related information in the interview component and medical, dental, and physiological information in the physical examination component [16]. Approximately 5,000 individuals are sampled through a complex probability cluster design on an annual basis. As a result, the NHANES 2005–2008 cycles had an initial sample of 20,497 people. Exclusions were made in sequence for age (<20 y: n = 9,583), BMI (<30 kg/m2: n = 13,499), pregnancy (n = 136), missing metabolic syndrome (MetS) components or implausible values (ntriglycerides = 241, nblood  pressure = 95, nwaist  circumference = 177, nHDL  cholesterol = 91, and nfasting  plasma  glucose = 1,686), and sleep duration (n = 7), leaving a final analytic sample of 1,777.

2.2. Metabolically Healthy Obesity and Metabolically Abnormal Obesity

The Joint Interim Statement for MetS was used as the indicator of cardiometabolic health in those living with obesity based on the BMI cut-off of ≥30 kg/m2 [17]. That is, those with ≤2 MetS components were classified as MHO: elevated waist circumference: men: ≥102 cm, women: ≥88 cm; elevated fasting triglycerides (≥1.69 mM) or medication; low HDL cholesterol: men: <1.04 mM, women: <1.29 mM, or medication; elevated systolic (≥130 mmHg) and/or diastolic (≥85 mmHg) blood pressure or medication; and elevated fasting plasma glucose (≥5.6 mM) or medication [10, 17]. Those with ≥3 of the above measures were classified as MAO [17].

2.3. Sleep Habits

NHANES administered the Sleep Disorders Questionnaire to individuals aged ≥16 y to assess typical sleep habits for the past month [16]. The Sleep Disorders Questionnaire contains items from two previously validated sleep questionnaires [18]. Information on the typical sleep duration (hours (h) per night) on weekdays or workdays was collected as whole numbers [1 to 11 and ≥12 h] from a single question [“How much sleep do you usually get at night on weekdays or workdays?”] [16]. The responses were categorized as ≤4, 5-6, 7-8, and ≥9 h per night [19, 20]. Overall sleep quality was determined from six questions that were used to obtain information on the sleeping habits of the participants in the past month: “How often did you have trouble falling asleep?”; “How often did you wake up during the night and had trouble getting back to sleep?”; “How often did you wake up too early in the morning and were unable to get back to sleep?”; “How often did you feel unrested during the day, no matter how many hours of sleep you have had?”; “How often did you feel excessively or overly sleepy during the day?”; and “How often did you not get enough sleep?” Responses to each question [0 = never; 1 = rarely (1 time a month); 2 = sometimes (2–4 times a month); 3 = often (5–15 times a month); and 4 = almost always (16–30 times a month)] were summed to obtain the overall sleep quality score, which was then categorized as good (0 to <3); fair (3 to <7); poor (7 to <12); and very poor (≥12 to 24) [21, 22].

2.4. Covariates

Age (20 to <40 y, 40 to <65 y, and ≥65 y), sex, ethnicity (Non-Hispanic White, Non-Hispanic Black, Mexican American, and Other), annual household income, education, alcohol intake, smoking history, leisure-time physical activity, and physician diagnosed sleep disorder were considered as covariates [10, 23]. Smoking was categorized as current, past (if smoked ≥100 cigarettes in one's life but not a current smoker), or never (if smoked <100 cigarettes in one's life) [10]. Educational attainment was categorized as <high school, high school, and college; income as <$20,000, $20,000–44,999, and ≥$45,000; and alcohol intake as 0, <3, and ≥3 drinks per day [23]. For leisure-time physical activity (PA), the metabolic equivalent (MET) scores provided by NHANES were used to calculate MET min/week, which were then categorized as no reported PA data, low PA (1 to 499 MET min/week), and guideline adherence (≥500 MET min/week) [10, 24]. Physician diagnosed sleep disorders were obtained from a single question [“Have you ever been told by a doctor or other health professional that you have a sleep disorder?”] [16].

2.5. Statistics

Mean and 95% confidence interval (CI) for continuous variables and percentage and 95% CI for categorical variables were determined for MHO versus MAO. Differences in demographic and behavioral characteristics were assessed with independent t-test and χ2 tests, as appropriate. The mean sleep duration and overall sleep quality score were compared by sex and MHO status. Logistic regression was subsequently used to estimate the odds ratio (OR, 95% CI) for MHO. The crude OR of MHO (ORc), odds of MHO adjusting for age, sex, ethnicity, education, income, smoking, alcohol, and leisure-time physical activity (ORadj), and the odds of MHO additionally adjusting for physician diagnosed sleep disorder (ORadj2) were estimated. The moderating effects of age, sex, and physician diagnosed sleep disorder on the overall relationship were also explored. All analyses were weighted with the medical exam sample weights using SAS v9.3 (Cary, NC, U.S.). Statistical significance was set at α of 0.05.

3. Results

Table 1 shows the sample characteristics, grouped by metabolic health status. Overall, 28.3% of the adults living with obesity had MHO. MHO individuals tended to be more active, younger, female, and never smokers and were also less likely to be have a physician diagnosed sleep disorder or belong to the Non-Hispanic White ethnic group (p < 0.05). MHO and MAO individuals did not differ in education (p = 0.05), income (p = 0.16), or alcohol intake (p = 0.05). The mean (95% CI) sleep duration between MHO and MAO was also not significantly different (MHO: 6.63 (6.47, 6.78) versus MAO: 6.70 (6.62, 6.78) hours); however, MHO had a slightly lower overall sleep quality score (8.34 (7.84, 8.83)) than MAO individuals (9.11 (8.69, 9.53)).

Table 1
Characteristics of the sample adult (≥20 y, obesity: BMI ≥ 30 kg/m2) population.

In crude and fully adjusted models, sleep duration and overall sleep quality were not related to MHO (Figure 1), and no significant interactions (e.g., age, sex, and physician diagnosed sleep disorder) were found (all p > 0.05). When individual sleep quality questions were assessed, a significant relationship was found for four of the six questions, wherein those who reported “almost always” (versus “never”) had lower odds of MHO (e.g., “How often did you have trouble falling asleep?”; “How often did you wake up during the night and had trouble getting back to sleep?”; “How often did you feel unrested during the day, no matter how many hours of sleep you have had?”; and “How often did you feel excessively or overly sleepy during the day?”) (Figure 2). Only two sleep quality questions were not associated with MHO (i.e., “How often did you wake up too early in the morning and were unable to get back to sleep?” and “How often did you not get enough sleep?”). However, no significant relationships between the sleep parameters and the individual cardiometabolic components were found (data not shown).

Figure 1
The odds of metabolically healthy obesity by sleep duration (a) and sleep quality (b) categories. Modeled for MHO (i.e., absence of metabolic syndrome according to the Joint Interim Statement, ≤2 cardiometabolic dysfunctions). Responses to sleep ...
Figure 2
The odds of metabolically healthy obesity for each sleep quality question. (a) “How often did you have trouble falling asleep?”; (b) “How often did you wake up during the night and had trouble getting back to sleep?”; (c) ...

4. Discussion

To our knowledge, this is the first population-based analysis to examine both sleep duration and sleep quality factors as they relate to MHO in free-living adults. Descriptively, MHO individuals reported slightly better overall sleep quality, but neither sleep duration nor overall sleep quality was associated with the odds of MHO in fully adjusted models. Nonetheless, regularly waking up during the night, feeling unrested during the day, feeling overly sleepy during the day, and trouble falling asleep were associated with lower odds of MHO. Therefore, our study provides novel evidence that specific sleep quality measures, but not sleep duration, are associated with the cardiometabolic health of people living with obesity.

4.1. Sleep Duration

Of the two previous studies that characterized the MHO versus MAO phenotype by sleep duration, one found a difference in women only [3], while the other supports our finding of no association [15]. In the study by Hankinson et al. [3] MHO women slept 7.6 h per day while MAO women slept 7.0 h. This is in contrast to our finding of no difference and may be attributed in part to Hankinson et al.'s [3] more conservative classification of MHO as the complete absence of diagnosed cardiometabolic abnormalities (versus the absence of preclinical Joint Interim Statement diagnostic cut-offs) [17] and their use of a slightly older sample. Although MHO tends to be younger than MAO and we did not find age was a moderator, the intersection of sleep and age requires further study [25], as both sleep duration and quality decrease [26], while cardiometabolic risk increases with age [27].

Further, chronic sleep deprivation promotes weight gain by altering specific endocrine pathways, such as leptin and ghrelin, that control appetite [28]. Sleep loss is also associated with higher preference for foods rich in fats and carbohydrates that promote weight gain [29]. Elevated sympathetic nervous system activity and higher inflammation have also been linked with poor sleep and obesity [30]. However, in the MHO phenotype, these potential mechanisms may remain intact while they may be compromised in the MAO phenotype [31]. Additionally, experimental evidence suggests that sleep loss results in metabolic consequences, including reduced nocturnal utilization of glucose that can promote insulin resistance and elevate diabetes risk in otherwise healthy individuals [28, 32]. A disproportionate number of individuals with diagnosed sleep disorders also have cardiometabolic dysfunction and obesity [33]. Therefore, although adequate sleep may be one of the common features that differentiate the MHO phenotype from the MAO phenotype, because of the complex interaction between sleep, obesity, and cardiometabolic dysfunction, the directionality of this relationship is not yet clear.

4.2. Sleep Quality

Results of this study suggest that select sleep quality measures, but not overall sleep quality, are associated with cardiometabolic health. These findings are supported by findings that poor sleep quality factors are related to obesity [34, 35], blood pressure [36], and glucose dysregulation [37, 38]. Indeed, individuals with obesity tend to have lower sleep quality and are more likely to experience a sleep disorder [39]. Mechanical [40] and physiological mechanisms [41] related to excess bodyweight could account in part for this decrease in sleep quality; however, whether obesity/higher bodyweight causes the decrease in sleep quality or vice versa remains unclear [30].

It remains to be seen whether overall sleep quality or efficiency, waking up during the night, daytime sleepiness, trouble falling asleep, sleep latency, or a combination of these factors is essential for cardiometabolic health and is an area in need of further study [21, 42]. Nonetheless, our study provides a new perspective on the complications of individuals with obesity in that MHO individuals have slightly better overall sleep quality than those with MAO, and selected sleep quality factors help predict the MHO phenotype. In our study, regularly reporting waking up during the night (i.e., 16–30 times a month), feeling unrested during the day, feeling overly sleepy during the day, and trouble falling asleep were moderately associated with the MHO phenotype [43]. However, some chronic conditions, for example, diabetes, hypertension, obesity (the clinical diagnosis), and depression, are also associated with fragmented sleep, insomnia, and excessive daytime sleepiness [44, 45]. Therefore, further research in this area is needed to better understand the relationship between various sleep quality factors and cardiometabolic health amongst those living with obesity/higher bodyweight.

4.3. Limitations

Several limitations exist with our study. First, due to the cross-sectional nature of our study, we cannot infer a causal relationship between sleep habits and MHO. Second, we were unable to assess the relationship between changing sleep patterns and napping within a 24 h period, which may give a better depiction of the sleep-MHO relationship. It is also possible that some yet to be assessed combination of sleep quantity and quality is a better predictor of MHO. Other cardiometabolic risk factors, such as percent body fat, HOMA-IR, and LDL-cholesterol, may also be indicators of the MHO phenotype but they were not included in our definition. Our definition for MHO compares favorably with much of the current literature, but MHO has been defined with many different definitions [46]. Further, we used self-reported sleep habits, which were susceptible to recall and healthy responder biases. Finally, we did not consider any other diseases (e.g., depression, coronary heart disease) or circumstances, such as shift-work, that affect sleep and circadian rhythm [47, 48]. Given the limitations of this study and current knowledge on the relationship between sleep and the MHO phenotype, research using objective measures of sleep within a longitudinal framework is needed. Particularly, studies to assess the importance of changing sleep patterns as they relate to the MHO versus MAO phenotypes are needed. Future research in this area should also quantify the contributions of other diseases and circumstances (mentioned above) to the sleep-MHO relationship.

5. Conclusions

Experiencing regular disturbances in sleep quality, but not overall sleep quality or sleep duration, is associated with MHO. Further studies in other populations living with obesity (i.e., higher bodyweight) are needed to confirm our findings.

Acknowledgments

This work was funded by a research grant (no. 131594) from the Canadian Institute of Health Research.

Competing Interests

The authors have no conflict of interests to declare.

References

1. James P. T. Obesity: the worldwide epidemic. Clinics in Dermatology. 2004;22(4):276–280. doi: 10.1016/j.clindermatol.2004.01.010. [PubMed] [Cross Ref]
2. Blüher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Current Opinion in Lipidology. 2010;21(1):38–43. doi: 10.1097/mol.0b013e3283346ccc. [PubMed] [Cross Ref]
3. Hankinson A. L., Daviglus M. L., Horn L. V., et al. Diet composition and activity level of at risk and metabolically healthy obese american adults. Obesity. 2013;21(3):637–643. doi: 10.1002/oby.20257. [PMC free article] [PubMed] [Cross Ref]
4. Calori G., Lattuada G., Piemonti L., et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese italian individuals: the cremona study. Diabetes Care. 2011;34(1):210–215. doi: 10.2337/dc10-0665. [PMC free article] [PubMed] [Cross Ref]
5. Kuk J. L., Ardern C. I. Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes Care. 2009;32(12):2297–2299. doi: 10.2337/dc09-0574. [PMC free article] [PubMed] [Cross Ref]
6. Hamer M., Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. Journal of Clinical Endocrinology and Metabolism. 2012;97(7):2482–2488. doi: 10.1210/jc.2011-3475. [PubMed] [Cross Ref]
7. Hamer M., Bell J. A., Sabia S., Batty G. D., Kivimäki M. Stability of metabolically healthy obesity over 8 years: the English longitudinal study of ageing. European Journal of Endocrinology. 2015;173(5):703–708. doi: 10.1530/eje-15-0449. [PubMed] [Cross Ref]
8. Kramer C. K., Zinman B., Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Annals of Internal Medicine. 2013;159(11):758–769. doi: 10.7326/0003-4819-159-11-201312030-00008. [PubMed] [Cross Ref]
9. Camhi S. M., Waring M. E., Sisson S. B., Hayman L. L., Must A. Physical activity and screen time in metabolically healthy obese phenotypes in adolescents and adults. Journal of Obesity. 2013;2013:10. doi: 10.1155/2013/984613.984613 [PMC free article] [PubMed] [Cross Ref]
10. Kanagasabai T., Thakkar N. A., Kuk J. L., Churilla J. R., Ardern C. I. Differences in physical activity domains, guideline adherence, and weight history between metabolically healthy and metabolically abnormal obese adults: a cross-sectional study. International Journal of Behavioral Nutrition and Physical Activity. 2015;12, article 64 doi: 10.1186/s12966-015-0227-z. [PMC free article] [PubMed] [Cross Ref]
11. Smith K. J., Bessell E., Magnussen C. G., Dwyer T., Venn A. J. Does youth adiposity, or change in adiposity from youth to adulthood, predict metabolically healthy obesity in adulthood? Pediatric Obesity. 2016;11(5):349–353. doi: 10.1111/ijpo.12065. [PubMed] [Cross Ref]
12. Phillips C. M. Metabolically healthy obesity: definitions, determinants and clinical implications. Reviews in Endocrine and Metabolic Disorders. 2013;14(3):219–227. doi: 10.1007/s11154-013-9252-x. [PubMed] [Cross Ref]
13. Camhi S. M., Whitney Evans E., Hayman L. L., Lichtenstein A. H., Must A. Healthy eating index and metabolically healthy obesity in U.S. adolescents and adults. Preventive Medicine. 2015;77:23–27. doi: 10.1016/j.ypmed.2015.04.023. [PubMed] [Cross Ref]
14. Alam I., Ng T. P., Larbi A. Does inflammation determine whether obesity is metabolically healthy or unhealthy? the aging perspective. Mediators of Inflammation. 2012;2012:14. doi: 10.1155/2012/456456.456456 [PMC free article] [PubMed] [Cross Ref]
15. Ryu J. Y., Lee J. S., Hong H. C., et al. Association between body size phenotype and sleep duration: Korean National Health and Nutrition Examination Survey v (KNHANES V) Metabolism: Clinical and Experimental. 2015;64(3):460–466. doi: 10.1016/j.metabol.2014.12.001. [PubMed] [Cross Ref]
16. National Center for Health Statistics. NHANES—About the National Health and Nutrition Examination Survey. 2011, http://www.cdc.gov/nchs/nhanes/about_nhanes.htm.
17. Alberti K. G. M. M., Eckel R. H., Grundy S. M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation. 2009;120(16):1640–1645. doi: 10.1161/circulationaha.109.192644. [PubMed] [Cross Ref]
18. Plantinga L., Lee K., Inker L. A., et al. Association of sleep-related problems with CKD in the United States, 2005–2008. American Journal of Kidney Diseases. 2011;58(4):554–564. doi: 10.1053/j.ajkd.2011.05.024. [PubMed] [Cross Ref]
19. Tamakoshi A., Ohno Y. Self-reported sleep duration as a predictor of all-cause mortality: results from the JACC Study, Japan. Sleep. 2004;27(1):51–54. [PubMed]
20. Gangwisch J. E., Malaspina D., Boden-Albala B., Heymsfield S. B. Inadequate sleep as a risk factor for obesity: analyses of the NHANES I. Sleep. 2005;28(10):1289–1296. [PubMed]
21. Engeda J., Mezuk B., Ratliff S., Ning Y. Association between duration and quality of sleep and the risk of pre-diabetes: evidence from NHANES. Diabetic Medicine. 2013;30(6):676–680. doi: 10.1111/dme.12165. [PMC free article] [PubMed] [Cross Ref]
22. Kanagasabai T., Ardern C. I. Inflammation, oxidative stress, and antioxidants contribute to selected sleep quality and cardiometabolic health relationships: a cross-sectional study. Mediators of Inflammation. 2015;2015:11. doi: 10.1155/2015/824589.824589 [PMC free article] [PubMed] [Cross Ref]
23. Kanagasabai T., Nie J. X., Mason C., Ardern C. I. Metabolic syndrome and prevalent any-site, prostate, breast and colon cancers in the U.S. adult population: NHANES 1999–2010. Journal of Metabolic Syndrome. 2014;3, article no. 135 doi: 10.4172/2167-0943.1000135. [Cross Ref]
24. Office of Disease Prevention and Health Promotion. Physical Activity Guidelines for Americans. Washington, DC, USA: US Department of Health and Human Services; 2008.
25. Unruh M. L., Redline S., An M.-W., et al. Subjective and objective sleep quality and aging in the sleep heart health study. Journal of the American Geriatrics Society. 2008;56(7):1218–1227. doi: 10.1111/j.1532-5415.2008.01755.x. [PubMed] [Cross Ref]
26. Ohayon M. M., Carskadon M. A., Guilleminault C., Vitiello M. V. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. 2004;27(7):1255–1273. [PubMed]
27. Khansari N., Shakiba Y., Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Patents on Inflammation and Allergy Drug Discovery. 2009;3(1):73–80. doi: 10.2174/187221309787158371. [PubMed] [Cross Ref]
28. Spiegel K., Knutson K., Leproult R., Tasali E., Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. Journal of Applied Physiology. 2005;99(5):2008–2019. doi: 10.1152/japplphysiol.00660.2005. [PubMed] [Cross Ref]
29. St-Onge M.-P., Wolfe S., Sy M., Shechter A., Hirsch J. Sleep restriction increases the neuronal response to unhealthy food in normal-weight individuals. International Journal of Obesity. 2014;38(3):411–416. doi: 10.1038/ijo.2013.114. [PMC free article] [PubMed] [Cross Ref]
30. Spiegel K., Tasali E., Leproult R., Van Cauter E. Effects of poor and short sleep on glucose metabolism and obesity risk. Nature Reviews Endocrinology. 2009;5(5):253–261. doi: 10.1038/nrendo.2009.23. [PMC free article] [PubMed] [Cross Ref]
31. Plourde G., Karelis A. D. Current issues in the identification and treatment of metabolically healthy but obese individuals. Nutrition, Metabolism and Cardiovascular Diseases. 2014;24(5):455–459. doi: 10.1016/j.numecd.2013.12.002. [PubMed] [Cross Ref]
32. Spiegel K., Leproult R., Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999;354(9188):1435–1439. doi: 10.1016/S0140-6736(99)01376-8. [PubMed] [Cross Ref]
33. Svatikova A., Wolk R., Gami A. S., Pohanka M., Somers V. K. Interactions between obstructive sleep apnea and the metabolic syndrome. Current Diabetes Reports. 2005;5(1):53–58. doi: 10.1007/s11892-005-0068-2. [PubMed] [Cross Ref]
34. Lyytikäinen P., Lallukka T., Lahelma E., Rahkonen O. Sleep problems and major weight gain: a follow-up study. International Journal of Obesity. 2011;35(1):109–114. doi: 10.1038/ijo.2010.113. [PubMed] [Cross Ref]
35. Watanabe M., Kikuchi H., Tanaka K., Takahashi M. Association of short sleep duration with weight gain and obesity at 1-year follow-up: a large-scale prospective study. Sleep. 2010;33(2):161–167. [PubMed]
36. Corbalán-Tutau M. D., Madrid J. A., Garaulet M. Timing and duration of sleep and meals in obese and normal weight women. Association with increase blood pressure. Appetite. 2012;59(1):9–16. doi: 10.1016/j.appet.2012.03.015. [PubMed] [Cross Ref]
37. Nilsson P. M., Rööst M., Engström G., Hedblad B., Berglund G. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care. 2004;27(10):2464–2469. doi: 10.2337/diacare.27.10.2464. [PubMed] [Cross Ref]
38. Barceló A., Barbé F., De La Peña M., et al. Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax. 2008;63(11):946–950. doi: 10.1136/thx.2007.093740. [PubMed] [Cross Ref]
39. Panossian L. A., Veasey S. C. Daytime sleepiness in obesity: Mechanisms beyond obstructive sleep apnea—a review. Sleep. 2012;35(5):605–615. doi: 10.5665/sleep.1812. [PubMed] [Cross Ref]
40. Kirkness J. P., Schwartz A. R., Schneider H., et al. Contribution of male sex, age, and obesity to mechanical instability of the upper airway during sleep. Journal of Applied Physiology. 2008;104(6):1618–1624. doi: 10.1152/japplphysiol.00045.2008. [PMC free article] [PubMed] [Cross Ref]
41. Scherrer U., Randin D., Tappy L., Vollenweider P., Jéquier E., Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994;89(6):2634–2640. doi: 10.1161/01.CIR.89.6.2634. [PubMed] [Cross Ref]
42. Cappuccio F. P., D'Elia L., Strazzullo P., Miller M. A. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010;33(2):414–420. doi: 10.2337/dc09-1124. [PMC free article] [PubMed] [Cross Ref]
43. Chen H., Cohen P., Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. Communications in Statistics—Simulation and Computation. 2010;39(4):860–864. doi: 10.1080/03610911003650383. [Cross Ref]
44. Bixler E. O., Vgontzas A. N., Lin H.-M., Calhoun S. L., Vela-Bueno A., Kales A. Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression. Journal of Clinical Endocrinology and Metabolism. 2005;90(8):4510–4515. doi: 10.1210/jc.2005-0035. [PubMed] [Cross Ref]
45. Cheng P., Pillai V., Mengel H., Roth T., Drake C. L. Sleep maintenance difficulties in insomnia are associated with increased incidence of hypertension. Sleep Health. 2015;1(1):50–54. doi: 10.1016/j.sleh.2014.11.004. [Cross Ref]
46. Durward C. M., Hartman T. J., Nickols-Richardson S. M. All-cause mortality risk of metabolically healthy obese individuals in NHANES III. Journal of Obesity. 2012;2012:12. doi: 10.1155/2012/460321.460321 [PMC free article] [PubMed] [Cross Ref]
47. Van Reeth O., Weibel L., Spiegel K., Leproult R., Dugovic C., Maccari S. Physiology of sleep (review)-interactions between stress and sleep: from basic research to clinical situations. Sleep Medicine Reviews. 2000;4(2):201–219. doi: 10.1053/smrv.1999.0097. [Cross Ref]
48. Fuller J. M., Wong K. K., Krass I., Grunstein R., Saini B. Sleep disorders screening, sleep health awareness, and patient follow-up by community pharmacists in Australia. Patient Education and Counseling. 2011;83(3):325–335. doi: 10.1016/j.pec.2011.05.004. [PubMed] [Cross Ref]

Articles from Journal of Obesity are provided here courtesy of Hindawi